Sector footprint
$889.4K in exports
Reported chemicals exports in 2024 across 31 qualifying HS6 products.
Sector export playbook ยท HS 28-38
Tuvalu Chemicals exports
where capability meets demand
Explore Tuvalu's HS 28-38 product portfolio, buyer markets, growth signals, and diversification opportunities. Use this guide to prioritize research, not to treat calculated indicators as guaranteed sales.
Sector exports$889.4K2024 reported value
Products31Qualifying HS6 products
Buyer markets7Markets represented
Average CAGR+3.9%Product-level growth signal
Global sector size$15.7BReported buyer imports
Chemicals capability
How strong is Tuvalu in this sector?
Compare exporter scale with product breadth, buyer demand, growth, and destination reach. A large sector does not remove the need for product, compliance, pricing, and buyer validation.
Global demand
$15.7B buyer imports
The sector's reported buyer import base provides context for product and market prioritization.
How to use the guide
Find the next credible move
Start with products that combine demand and exporter capability, then validate standards, route economics, buyers, and competition.
Product portfolio
Which products anchor the sector?
Each HS6 product is ranked by calculated opportunity and shown with reported market size, exporter exports, growth, and destination reach.
| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
|---|---|---|---|---|---|---|
| HS 300215Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $13.6B | $3.8K | $5.2B | +13.2% | 1 | +0.0% |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | $1.6B | $594.9 | $1.0B | +34.6% | 1 | +0.0% |
| HS 293359Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $375.3M | $373.8K | $125.6M | +126.7% | 1 | +0.2% |
| HS 382491Chemical products, mixtures and preparations: consisting mainly of (5-ethyl-2-methyl-2-oxido-1,3,2-dioxaphosphinan-5-yl)methyl methyl methylphosphonate and bis[(5-ethyl-2-methyl-2-oxido-1,3,2-dioxaphosphinan-5-yl)methyl] methylphosphonate | $46.5M | $594.9 | $77.0M | +34.6% | 1 | +0.0% |
| HS 300490Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $23.6M | $315.1 | $9.9M | -25.4% | 2 | +0.0% |
| HS 293980Alkaloids: natural or reproduced by synthesis, and their salts, esters and other derivatives n.e.c. in heading no. 2939 | $3.5M | $373.8K | $3.2M | +126.7% | 1 | +16.1% |
| HS 300220Vaccines: for human medicine | $5.2M | $12.7 | $2.8M | +4.8% | 1 | +0.0% |
| HS 300390Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.0M | $20.6 | $2.0M | +8.9% | 1 | +0.0% |
| HS 382484Chemical products, mixtures and preparations: containing aldrin, camphechlor (toxaphene), chlordane, chlordecone, DDT (chlorfenotane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane), dieldrin, endosulfan, endrin, heptachlor or mirex | $1.6M | $594.9 | $1.6M | +34.6% | 1 | +0.0% |
| HS 382488Chemical products, mixtures and preparations: containing goods specified in Subheading Note 3 to this Chapter: containing tetra-, penta-, hexa-, hepta- or octabromodiphenyl ethers | $1.4M | $594.9 | $1.3M | +34.6% | 1 | +0.1% |
| HS 300439Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $1.6M | $9.3 | $1.1M | -25.0% | 1 | +0.0% |
| HS 300450Medicaments: containing vitamins or their derivatives, for therapeutic or prophylactic use, packaged for retail sale | $1.1M | $4.3 | $921.0K | -33.9% | 1 | +0.0% |
| HS 300590Wadding, gauze, bandages and similar articles: (excluding adhesive dressings), impregnated or coated with pharmaceutical substances, packaged for retail sale | $1.3M | $5.4 | $878.4K | -21.5% | 1 | +0.0% |
| HS 300410Medicaments: containing penicillins, streptomycins or their derivatives, for therapeutic or prophylactic uses, packaged for retail sale | $1.2M | $10.8 | $671.1K | -32.9% | 1 | +0.0% |
| HS 292690Nitrile-function compounds: n.e.s. in heading no. 2926 | $2.1M | $81.5K | $622.1K | -25.9% | 1 | +2.5% |
| HS 320890Paints and varnishes: based on polymers n.e.s. in heading no. 3208, dispersed or dissolved in a non-aqueous medium | $1.2M | $23.5 | $527.3K | +3.5% | 1 | +0.0% |
| HS 300320Medicaments: containing antibiotics other than penicillins, streptomycins and their derivatives, for therapeutic or prophylactic uses, (not in measured doses, not packaged for retail sale) | $692.2K | $29.6 | $358.8K | +0.8% | 1 | +1.0% |
| HS 300510Dressings, adhesive: and other articles having an adhesive layer, packed for retail sale for medical, surgical, dental or veterinary purposes | $571.3K | $7.5 | $344.2K | -10.6% | 1 | +0.0% |
| HS 300290Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $321.3K | $1.3 | $333.4K | +2.5% | 1 | +0.0% |
| HS 330610Oral or dental hygiene preparations: dentifrices | $524.1K | $46.9K | $275.8K | +8.4% | 1 | +14.6% |
| HS 381900Hydraulic fluids: for brakes and other prepared liquids for hydraulic transmission, not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $492.9K | $6.1K | $240.8K | +56.8% | 1 | +1.0% |
| HS 382487Chemical products, mixtures and preparations: containing goods specified in Subheading Note 3 to this Chapter: containing perfluorooctane sulphonic acid, its salts, perfluorooctane sulphonamides, or perfluorooctane sulphonyl fluoride | $192.1K | $594.9 | $213.2K | +34.6% | 1 | +1.8% |
| HS 382478Mixtures containing halogenated derivatives of methane, ethane or propane: containing perfluorocarbons (PFCs) or hydrofluorocarbons (HFCs), but not containing chlorofluorocarbons (CFCs) or hydrochlorofluorocarbons (HCFCs) | $261.9K | $1.2 | $209.8K | +5.3% | 1 | +0.0% |
| HS 300420Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $536.8K | $4.9 | $209.4K | -48.3% | 1 | +0.0% |
| HS 300660Pharmaceutical goods: chemical contraceptive preparations based on hormones or spermicides | $328.1K | $1.5 | $164.7K | -30.5% | 1 | +0.0% |
| HS 330499Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $190.7K | $1.8 | $140.5K | -22.3% | 1 | +0.0% |
| HS 300610Pharmaceutical goods: sterile surgical catgut, suture materials, tissue adhesives, laminaria, laminaria tents, absorbable surgical or dental haemostatics, and surgical or dental adhesion barriers | $152.7K | $4.3 | $119.6K | -32.4% | 1 | +0.0% |
| HS 300630Pharmaceutical goods: opacifying preparations for x-ray examinations, diagnostic reagents designed to be administered to the patient | $163.9K | $2.6 | $105.9K | -18.3% | 1 | +0.0% |
| HS 283620Carbonates: disodium carbonate | $84.2K | $13.0 | $74.5K | +1.1% | 1 | +0.0% |
| HS 300432Medicaments: containing corticosteroid hormones, their derivatives or structural analogues (but not containing antibiotics), for therapeutic or prophylactic uses, packaged for retail sale | $98.9K | $1.6 | $70.2K | -61.2% | 1 | +0.0% |
| HS 382590Residual products of the chemical or allied industries, not elsewhere specified or included: n.e.c. in 3825 or 27.10 | $50.5K | $0.4 | $41.8K | +5.4% | 1 | +0.0% |
Best markets
Where does sector demand concentrate?
Markets are ranked by calculated opportunity across the qualifying products in this sector view.
NLD
Netherlands
1 products represented in the sector.
$5.2B$13.6B reported buyer importsFRA
France
5 products represented in the sector.
$1.1B$1.6B reported buyer importsGBR
United Kingdom
2 products represented in the sector.
$128.8M$378.8M reported buyer importsFJI
Fiji
20 products represented in the sector.
$19.8M$38.6M reported buyer importsKNA
Saint Kitts and Nevis
2 products represented in the sector.
$1.5M$3.5M reported buyer importsSVN
Slovenia
1 products represented in the sector.
$622.1K$2.1M reported buyer importsPNG
Papua New Guinea
1 products represented in the sector.
$275.8K$524.1K reported buyer importsGrowth stars
Which products show the strongest growth?
Average product-level CAGR is a screening signal. Confirm the latest trend, base effects, buyer quality, and commercial feasibility before acting.
| Product | Average CAGR | Opportunity | Markets |
|---|---|---|---|
| HS 293359Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | +126.7% | $125.6M | 1 |
| HS 293980Alkaloids: natural or reproduced by synthesis, and their salts, esters and other derivatives n.e.c. in heading no. 2939 | +126.7% | $3.2M | 1 |
| HS 381900Hydraulic fluids: for brakes and other prepared liquids for hydraulic transmission, not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | +56.8% | $240.8K | 1 |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | +34.6% | $1.0B | 1 |
| HS 382491Chemical products, mixtures and preparations: consisting mainly of (5-ethyl-2-methyl-2-oxido-1,3,2-dioxaphosphinan-5-yl)methyl methyl methylphosphonate and bis[(5-ethyl-2-methyl-2-oxido-1,3,2-dioxaphosphinan-5-yl)methyl] methylphosphonate | +34.6% | $77.0M | 1 |
| HS 382484Chemical products, mixtures and preparations: containing aldrin, camphechlor (toxaphene), chlordane, chlordecone, DDT (chlorfenotane, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane), dieldrin, endosulfan, endrin, heptachlor or mirex | +34.6% | $1.6M | 1 |
| HS 382488Chemical products, mixtures and preparations: containing goods specified in Subheading Note 3 to this Chapter: containing tetra-, penta-, hexa-, hepta- or octabromodiphenyl ethers | +34.6% | $1.3M | 1 |
| HS 382487Chemical products, mixtures and preparations: containing goods specified in Subheading Note 3 to this Chapter: containing perfluorooctane sulphonic acid, its salts, perfluorooctane sulphonamides, or perfluorooctane sulphonyl fluoride | +34.6% | $213.2K | 1 |
| HS 300215Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | +13.2% | $5.2B | 1 |
| HS 300390Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | +8.9% | $2.0M | 1 |
Diversification opportunities
Which products reach the widest buyer base?
Destination count is a simple breadth indicator. It does not measure destination concentration or guarantee resilience.
HS 300490
Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale
2 markets$9.9M calculated opportunityHS 300215
Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale
1 markets$5.2B calculated opportunityHS 382499
Chemical products, mixtures and preparations: n.e.c. heading 3824
1 markets$1.0B calculated opportunityHS 293359
Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof
1 markets$125.6M calculated opportunityHS 382491
Chemical products, mixtures and preparations: consisting mainly of (5-ethyl-2-methyl-2-oxido-1,3,2-dioxaphosphinan-5-yl)methyl methyl methylphosphonate and bis[(5-ethyl-2-methyl-2-oxido-1,3,2-dioxaphosphinan-5-yl)methyl] methylphosphonate
1 markets$77.0M calculated opportunityHS 293980
Alkaloids: natural or reproduced by synthesis, and their salts, esters and other derivatives n.e.c. in heading no. 2939
1 markets$3.2M calculated opportunityHS 300220
Vaccines: for human medicine
1 markets$2.8M calculated opportunityHS 300390
Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale)
1 markets$2.0M calculated opportunityFrequently asked questions
Using the Chemicals export playbook
Practical guidance for interpreting sector scale, growth, product breadth, and buyer markets.
How strong is Tuvalu in this sector?
Compare sector exports, product breadth, buyer markets, growth, and global demand. These signals identify research priorities rather than guarantee market access.
What are growth stars?
Products with higher average reported growth in the screened rows. Validate the time period, base effects, buyer demand, and current exporter position.
What does diversification mean here?
Products reaching more buyer markets in the screened data. Destination breadth is useful context but does not replace concentration, route, or buyer analysis.
Data source
OECD trade statistics with CEPII context
OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). OECD BIMTS is the primary trade series for this view. Supporting bilateral trade context uses CEPII BACI bilateral trade flows (202601) under Etalab 2.0 Open Licence. Yugalinks presents derived views of reported observations and calculated indicators. Data terms: OECD Terms & Conditions.